Here are the DEF 14A proxy statements from CalciMedica, Inc. (CALC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CALC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CALC filings page.
CalciMedica, Inc. is asking stockholders to vote at the virtual 2026 annual meeting on August 19, 2026. Holders of 30,736,401 shares of common stock outstanding as of July 21, 2026 are entitled to one vote per share.
Key items include electing two Class III directors, ratifying Baker Tilly US, LLP as auditor for 2026, amending the Amended 2023 Equity Incentive Plan to add 7,500,000 shares (for a total of 12,333,690) and broadening the evergreen calculation, advisory votes on executive pay and its frequency, and authority to implement a reverse stock split between 1-for-2 and 1-for-10 with a proportionate reduction in authorized common shares, at the Board’s discretion if approved. Stockholders are also asked to approve, for Nasdaq Listing Rule 5635(d) and 5635(c) purposes, issuances under a June 23, 2026 Purchase Agreement, including Series A and B Warrants for up to 18,673,429 shares each and separate director and officer tranches of 1,680,565 shares each. The Board recommends voting FOR all proposals and a one-year say-on-pay frequency.